From Wikipedia, the free encyclopedia
Chemical compound
GYKI 52895
Other names 4-(8,9-Dihydro-8-methyl-7H -1,3-dioxolo[4,5-h ][2,3]benzodiazepin-5-yl)benzenamine
4-{13-methyl-4,6-dioxa-11,12-diazatricyclo[7.5.0.03,7 ]tetradeca-1,3(7),8,10-tetraen-10-yl}aniline
CAS Number
PubChem
CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (
EPA )
Formula C 17 H 17 N 3 O 2
Molar mass 295.342 g·mol−1 3D model (
JSmol )
O1c2c(OC1)cc3c(c2)C(=N/NC(C3)C)\c4ccc(N)cc4
InChI=1S/C17H17N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8,10,19H,6,9,18H2,1H3
Y Key:AQTITSBNGSVQNZ-UHFFFAOYSA-N
Y
(verify)
GYKI 52895 is a drug which is a 2,3-
benzodiazepine derivative that also shares the
3,4-methylenedioxyamphetamine
pharmacophore . Unlike other similar drugs, GYKI 52895 is a selective
dopamine reuptake inhibitor (DARI),
[1]
[2] which appears to have an atypical mode of action compared to other DARIs.
[3] Its DRI activity is shared by numerous addictive drugs including
amphetamine and its derivatives (e.g.
dextromethamphetamine ),
cocaine , and
methylphenidate and its derivatives (e.g.
ethylphenidate ). However, dopaminergic drugs are also prone to producing
emetic effects such as in the case of
apomorphine .
Egis Pharmaceuticals began clinical development of the drug in 1997 for
major depressive disorder and
Parkinson's disease , but it was discontinued in 2001.
[4]
See also
References
^ Horváth K, Szabó H, Pátfalusi M, Berzsenyi P, Andrási F (1990). "Pharmacological Effects of GYKI 52895, a New Selective Dopamine Uptake Inhibitor". European Journal of Pharmacology . 183 (4): 1416–1417.
doi :
10.1016/0014-2999(90)94548-C .
^ Huang CL, Chen HC, Huang NK, Yang DM, Kao LS, Chen JC, et al. (June 1999).
"Modulation of dopamine transporter activity by nicotinic acetylcholine receptors and membrane depolarization in rat pheochromocytoma PC12 cells" . Journal of Neurochemistry . 72 (6): 2437–44.
doi :
10.1046/j.1471-4159.1999.0722437.x .
PMID
10349853 .
^ Vaarmann A, Gandhi S, Gourine AV, Abramov AY (2010). "Novel pathway for an old neurotransmitter: dopamine-induced neuronal calcium signalling via receptor-independent mechanisms". Cell Calcium . 48 (2–3): 176–82.
doi :
10.1016/j.ceca.2010.08.008 .
PMID
20846720 .
^
"GYKI 52895" . Adis Insight.
DAT Tooltip Dopamine transporter (
DRIs Tooltip Dopamine reuptake inhibitors )
NET Tooltip Norepinephrine transporter (
NRIs Tooltip Norepinephrine reuptake inhibitors )
Others:
Antihistamines (e.g.,
brompheniramine ,
chlorphenamine ,
pheniramine ,
tripelennamine )
Antipsychotics (e.g.,
loxapine ,
ziprasidone )
Arylcyclohexylamines (e.g.,
ketamine ,
phencyclidine )
Dopexamine
Ephenidine
Ginkgo biloba
Indeloxazine
Nefazodone
Opioids (e.g.,
desmetramadol ,
methadone ,
pethidine (meperidine) ,
tapentadol ,
tramadol ,
levorphanol )
SERT Tooltip Serotonin transporter (
SRIs Tooltip Serotonin reuptake inhibitors )
Others:
A-80426
Amoxapine
Antihistamines (e.g.,
brompheniramine ,
chlorphenamine ,
dimenhydrinate ,
diphenhydramine ,
mepyramine (pyrilamine) ,
pheniramine ,
tripelennamine )
Antipsychotics (e.g.,
loxapine ,
ziprasidone )
Arylcyclohexylamines (e.g.,
3-MeO-PCP ,
esketamine ,
ketamine ,
methoxetamine ,
phencyclidine )
Cyclobenzaprine
Delucemine
Dextromethorphan
Dextrorphan
Efavirenz
Hypidone
Medifoxamine
Mesembrine
Mifepristone
MIN-117 (WF-516)
N-Me-5-HT
Opioids (e.g.,
dextropropoxyphene ,
methadone ,
pethidine (meperidine) ,
levorphanol ,
tapentadol ,
tramadol )
Roxindole
VMATs Tooltip Vesicular monoamine transporters Others